Short and long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel following percutaneous coronary intervention: Results from CREDO

被引：0

作者：

Beinart, S

Kolm, P

Veledar, E

Zhang, ZF

Mahoney, E

Gabriel, S

Steinhubl, S

Weintraub, WS

机构：

[1] Emory Univ, Atlanta, GA 30322 USA

[2] Sanofi Synthelabo, Paris, France

[3] Univ N Carolina, Chapel Hill, NC 27599 USA

来源：

CIRCULATION | 2003年 / 108卷 / 17期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3495

引用

页码：775 / 775

页数：1

共 50 条

[1] Long-term cost-effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel following percutaneous coronary intervention (CREDO trial): A four-European country analysis
Weintraub, WS
Bouin, O
Veledar, E
Gabriel, S
VALUE IN HEALTH, 2005, 8 (03) : 262 - 262
[2] Long-term cost effectiveness of early and sustained antiplatelet therapy with clopidogrel following percutaneous coronary intervention (CREDO trial): a five European country analysis
Weintraub, W. S.
Bouin, O.
Veledar, E.
Kolm, G. P.
Gabriel, S.
EUROPEAN HEART JOURNAL, 2005, 26 : 552 - 552
[3] Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention - Results from The Clopidogrel for the Reduction of Events During Observation (CREDO) trial
Beinart, SC
Kolm, P
Veledar, E
Zhang, ZF
Mahoney, EM
Bouin, O
Gabriel, S
Jackson, J
Chen, R
Caro, J
Steinhubl, S
Topol, E
Weintraub, WS
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (05) : 761 - 769
[4] Short and long-term cost-effectiveness of early and sustained dual oral antiplatelet therapy with clopidrogrel following percutaneous coronary intervention: A Canadian economic analysis
Kolm, P
Veledar, E
Forte, L
Amin, M
Bouin, O
Jackson, J
Gabriel, S
Weintraub, WS
VALUE IN HEALTH, 2005, 8 (03) : 276 - 276
[5] The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: A Swedish analysis of the CREDO trial
Ringborg A.
Lindgren P.
Jönsson B.
The European Journal of Health Economics, 2005, 6 (4) : 354 - 362
[6] 9301 cost-effectiveness of long-term therapy with clopidogrel following percutaneous coronary intervention:: A Swedish analysis of the CREDO-trial
Ringborg, A
Lindgren, P
Jönsson, B
VALUE IN HEALTH, 2005, 8 (03) : 253 - 253
[7] Smoking influences the effectiveness of dual antiplatelet therapy on long-term outcomes following percutaneous coronary intervention
Kiran, YA
Steinhubl, SR
Hsu, AP
Topol, EJ
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 36B - 36B
[8] Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention - A randomized controlled trial
Steinhubl, SR
Berger, PB
Mann, JT
Fry, ETA
DeLago, A
Wilmer, C
Topol, EJ
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (19): : 2411 - 2420
[9] Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention
Mehta, SR
Yusuf, S
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (04) : 79S - 88S
[10] Long-term dual antiplatelet therapy and concomitant optimal medical therapy following percutaneous coronary intervention
Gargiulo, Giuseppe
Valgimigli, Marco
CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2017, 7 : S102 - S106

← 1 2 3 4 5 →